Evidence map›Paper›PMID 27883295›Full record

ArticlePharmacogenomics2016

Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer.

Tristan M Sissung, John Deeken, Crystal R Leibrand, Douglas K Price, Sheryl Ehrlich, Seth M Steinberg, David J Liewehr, William Dahut, William D Figg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacogenomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tristan M SissungClinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA.
John DeekenInova Comprehensive Cancer & Research Institute, Falls Church, VA 22042, USA.
Crystal R LeibrandClinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA.
Douglas K PriceMolecular Pharmacology Program, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA.
Sheryl EhrlichMolecular Pharmacology Program, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA.
Seth M SteinbergBiostatistics & Data Management Section, Office of the Clinical Director, National Cancer Institute, NIH, Shady Grove, MD 20850, USA.
David J LiewehrBiostatistics & Data Management Section, Office of the Clinical Director, National Cancer Institute, NIH, Shady Grove, MD 20850, USA.
William DahutProstate Cancer Clinical Research Section, Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
William D FiggClinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD 20892, USA.

Funding

Identify SNPs and Polymorphisms Involved in the Development of Prostate CancerZIABC010453 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$10.4M
Drug Development for Prostate Cancer and other Metastatic ProcessesZIABC010547 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$10.2M
6 · The paper itself

Abstract

aimMetabolism and transport play major roles in life-long exposure to endogenous and exogenous carcinogens. We therefore explored associations between polymorphisms in absorption, distribution, metabolism and elimination genes and the risk and prognosis of castration-resistant prostate cancer (CRPC). MATERIALS &

methodsA total of 634 genotypes were tested in 74 patients using the Affymetrix DMETv1.0 platform.

resultsNo relation to risk was found. Three SNPs were associated with CRPC prognosis in Caucasians: ABCB11 rs7602171G>A (p = 0.003; n = 30; hazard ratio [HR]: 0.307), GSTP1 rs1799811C>T (p = 0.001; n = 38; HR: 0.254) and SLC5A6 rs1395 (p = 0.004; n = 35; HR: 3.15). Two other polymorphisms among Caucasians were associated with interesting trends: ABCB4 rs2302387C>T (p = 0.039) and ABCC5 rs939339A>G (p = 0.018).

conclusionThis exploratory study is the first to show that polymorphisms in several absorption, distribution, metabolism and elimination genes may be associated with CRPC prognosis.

Indexed as

Polymorphism, Single NucleotideAdultAgedATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 11GenotypeGlutathione S-Transferase piHumansMaleMiddle AgedPrognosisProstatic Neoplasms, Castration-ResistantRiskSymportersABCB11 protein, humanATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 11biotin transporterGlutathione S-Transferase piGSTP1 protein, humanSymporterscastration-resistant prostate cancergenotypemetabolismoutcomesurvivaltransport

Identifiers

PMID27883295
PMCPMC5558514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.